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S U M M A R Y
Zoonotic schistosomiasis has a long endemic history in the Philippines. Human mass drug
administration has been the cornerstone of schistosomiasis control in the country for the past three
decades. Recent publications utilizing retrospective national survey data have indicated that the national
human prevalence of the disease is <1%, hence the disease is now close to elimination. However, the
evidence for such a claim is weak, given that less than a third of the human population is currently being
treated annually within endemic zones and only a third of those treated actually swallow the tablets. For
those who consume the drug at the single oral dose of 40 mg/kg, the estimated cure rate is 52% based on a
recent meta-analysis. Thus, approximately 5% of the endemic human population is in reality receiving
the appropriate treatment. To compound this public health problem, most of the bovines in the endemic
communities are concurrently infected but are not treated under the current national control
programme. Given this evidence, it is believed that the human prevalence of schistosomiasis within
endemic regions has been grossly underestimated. Inherent ﬂaws in the reporting of national
schistosomiasis prevalence data are reported here, and the problems of utilizing national retrospective
data in making geographic information system (GIS) risk maps and advising policy makers of the
outcomes are highlighted.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Schistosomiasis, or Bilharzia, is a neglected tropical parasitic
disease caused by blood ﬂukes of the genus Schistosoma. Globally,
it ranks third among the most devastating tropical diseases, and is
a major cause of morbidity in the tropics. Schistosomiasis was ﬁrst
reported in the Philippines in 1906.1 Approximately 12 million
people, residing in 28 endemic provinces located in 12 different
geographical zones, are at risk of infection in the country.2 Overall,
a total of 190 municipalities and 1212 barangays (villages) are
currently endemic for the disease based on surveys conducted over
the past decade. Two new endemic foci reported in the northern
(Gonzaga, Cagayan) and central (Calatrava, Negros Occidental)* Corresponding author: Grifﬁth University, Logan Campus, University Drive,
Meadowbrook QLD 4131, Australia. Tel.: +61 733821098.
E-mail address: a.ross@grifﬁth.edu.au (A.G. Ross).
http://dx.doi.org/10.1016/j.ijid.2016.01.011
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).parts of the country were conﬁrmed in 2004 and 2006,
respectively.3
Considerable optimism surrounds mass drug administration
(MDA) for the control of schistosomiasis globally, for which
praziquantel has served as the cornerstone since its development
in 1979.4 Numerous studies have claimed that preventive
chemotherapy (i.e., 40 mg/kg of praziquantel), given annually or
biannually, can signiﬁcantly reduce the prevalence and intensity of
infection, and control morbidity in the long term.4 In the last
decade, close to one billion US dollars has been raised for MDA
campaigns against neglected tropical diseases, largely from
international donors, and delivered vertically to local endemic
communities through national health care services.4
There is now strong evidence that large mammals (e.g., water
buffaloes, cattle, and dogs) are contributing signiﬁcantly to disease
transmission and complicating control.4 Given the zoonotic nature
of the disease in the Philippines it is evident that the incidence,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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MDA alone. There is the need for innovative cost-effective
strategies to control schistosomiasis japonica in the long term.
The inherent ﬂaws in the reporting of the national schistosomiasis
prevalence data are described herein, and the problems of utilizing
national retrospective data in making geographic information
system (GIS) risk maps and advising policy-makers of the
outcomes is highlighted.
2. National schistosomiasis surveillance
The control programme for schistosomiasis in the Philippines
has been under the supervision of the Schistosomiasis Control
Service (SCS). The human prevalence of Schistosoma japonicum
infection was deﬁned as the proportion of individuals who showed
at least one parasite egg on two Kato–Katz (KK) thick smears
versus the number of people examined in the endemic population.
The estimated exposed population for schistosomiasis in the
Philippines is approximately 1.8 million.2 The annual results of
case ﬁnding are shown in Table 1. From 1985 to 1990,
approximately 30% (range 26–37%) of the target population was
examined. In 1990, the SCS received additional funds from the
World Bank through the Philippine Health Development Pro-
gramme (PHDP), and from 1991 to 1993 it managed to examine
approximately 75% of the target population (range 75–79%) with
the increased funding. However, funds through the PHDP were
subsequently reduced in 1994 and funding was eventually
terminated in 1995. As a direct result, the proportion of individuals
examined annually from 1994 to 1999 decreased to approximately
25% (range 22–44%). The percentage of individuals examined
plummeted further from 2000 to the present.5–7 In sum, due to
limited ﬁnancial resources, active surveillance for schistosomiasis
in the Philippines now comprises approximately 10% of the known
endemic population in the country. This has resulted in a gross
underreporting of the disease given its highly focal nature and
clumped distribution.
With support from World Health Organization (WHO), a
stratiﬁed two-step systematic cluster sampling survey was
conducted from 2005 to 2008 in order to determine the national
prevalence of schistosomiasis.8 Provinces in both endemic and
non-endemic regions were identiﬁed for inclusion in the survey.
Five municipalities were selected randomly from the selected
provinces, and one village per municipality was selected for
follow-up. Two hundred and seventy-four eligible subjects wereTable 1
Reported human prevalence of schistosomiasis based on national survey dataa
Year Number of
individuals
examined
Percentage of
target population
of 1.8 million
individuals
Number
positive
Prevalence (%)
1985 505 851 28.6 39 046 10.4
1986 459 291 26 34 150 7.4
1987 683 918 37 44 925 6.6
1988 423 708 24 26 953 6.4
1989 468 355 27 35 197 7.5
1990 528 359 30 34 611 6.6
1991 1 317 933 75 79 500 6.0
1992 1 326 283 75 55 896 4.2
1993 1 402 216 79 54 648 3.9
1994 771 970 44 40 446 5.2
1995 267 346 15 12 091 4.5
1996 374 262 21 15 293 4.1
1997 404 811 23 18 301 4.5
1999 392 133 22 12 871 3.3
a Note: From 1985 to 1999, case ﬁnding was done by examining two Kato–Katz
thick smears from a single stool sample. Source of data: Department of Health
Schistosomiasis Control Service annual reports, 1997 and 1999.chosen randomly from the selected households in each village, and
eligible subjects were requested to submit two stool samples.8
From each stool sample, two KK thick smears were examined for
the presence of S. japonicum eggs. This sampling strategy selected
115 villages out of a total 1212 known endemic villages.
Compliance for the ﬁrst stool submission of eligible subjects
was 45% in Mindanao, 60% in the Visayas, and 76% in Luzon.8 It is
noteworthy that this national survey strategy examined less than
10% of the known endemic population and many individuals
refused to provide stool for examination. Thus the generalizability
of these ﬁndings for ‘endemic zones’ is questionable and should
be viewed with considerable caution. It is well known that the
distribution of the disease is highly focal (clumped) in nature, thus
the random selection of a small segment of the endemic population
(<10%) could lead to a gross underestimation of the true burden.
This combined with the fact that only one or two slides were read
for each individual raises concerns in the reporting of national
prevalence in the Philippines.
3. Problems with the national control programme
Population-based chemotherapy as the sole control strategy
for zoonotic schistosomiasis in the Philippines was initiated in
1980. The initial approach was the treatment of positive cases with
the drug praziquantel, administered at an oral dose of 60 mg/kg,
divided into two equal doses taken 4 h apart. The compliance rate
from 1985 to 1999 for annual free treatment was reportedly high at
approximately 85% in those who were found positive by case
ﬁnding. However, it is important to note that only 30% of the
endemic population was covered by yearly case ﬁnding and
treatment. This suggests that 70% of the endemic population was
left untreated.
In 2000, the SCS implemented a policy of annual MDA for
residents 5–65 years of age residing in endemic villages with a
human prevalence of infection greater than 15%. Case ﬁnding and
treatment was continued in villages with a prevalence of <15%.9 In
2009 the MDA policy was changed to provide treatment to all
individuals aged 5–65 years residing in endemic villages regardless
of the prevalence.10 In 2011, following the recommendation of
the WHO, the SCS reduced the dosage of praziquantel in the MDA
programme to a single oral dose of 40 mg/kg.11
Despite the fact that only a third of the infected population was
treated annually (except from 1991 to 1993) through the case
ﬁnding and treatment scheme, and that less than a third complied
with the free treatment, the yearly national prevalence of
S. japonicum in the country was reported to have declined
dramatically from a high of 10% in 1985 to a low of 0.49% in
2008. Table 1 illustrates the continuous drop in national human
prevalence of schistosomiasis from more than 10% in 1985 to less
than 4% in 1999. The prevalence was reportedly maintained at less
than 5% until 2005.5,6,12 Subsequent prevalence surveys (2005–
2008) using the above-mentioned stratiﬁed two-step systematic
cluster sampling approach, recorded a very low national level of
infection of less than 1%.8 The remarkably low national prevalence
reported for S. japonicum infection in the last 10 years has now
created the impression that the disease is no longer a serious public
health problem by the government and that the continuous
implementation of the existing national MDA programme for
humans could lead to disease elimination. However, given the poor
drug coverage (less than one third of the endemic population
covered) and poor compliance with the free annual treatment
(only one third of the population actually take the drug), it is
difﬁcult to believe that the current national human prevalence has
dropped to <1%. Moreover, given the zoonotic nature of the
disease, where over 80% of bovines are infected, the likelihood of a
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what is the true burden of this disease within endemic zones?
4. National burden of disease
Figure 1 summarizes the national schistosomiasis prevalence
for humans reported by Leonardo et al. in 2012, Magalha˜es et al. in
2014, and by various other authors during 2002–2014 in known
endemic zones.8,16 The national survey conducted in 2008, which
used the stratiﬁed two-step systematic cluster sampling scheme,
recorded very low prevalence rates in the known highly endemic
provinces of Western Samar, Northern Samar, and Leyte, with
reported prevalence rates of 0.8%, 2.4%, and 0.9%, respectively.8 In
the newly identiﬁed areas of transmission in Cagayan Province,
the recorded prevalence was 0.4%.8 The prevalence rates generated
by Magalha˜es et al. in 2014 for the same endemic provinces were
0–3%, 0–3%, 0–5%, and 0.4%.16 In contrast, other research teams
performing studies from 2002 to 2014 reported prevalence rates
ranging from 0.7% to 47% for Western Samar, 5% to 46% for
Northern Samar, and 25% to 60% for Leyte (Table 2). In Cagayan,
two endemic villages were surveyed and the prevalence rates
were found to be 10% and 31%, respectively.
Table 2 illustrates the key outcomes of various studies that have
investigated the prevalence of schistosomiasis in various endemic
regions throughout the country from 2002 to 2014. In 2002, a
longitudinal study completed in Leyte, investigating immune
correlates of resistance to infection, showed that the human
prevalence in those aged 15–30 years was 60% (1262/1699).17
Another study, which examined S. japonicum infection among
pregnant women, conducted in Leyte between 2008 and 2012,
showed that 25.4% (373/1468) of the subjects were positive for
schistosomiasis.18 A cross-sectional survey of 50 endemic villages
in Western Samar Province in 2006, as part of the Schistosomiasis
Transmission Ecology Project (STEP), reported prevalence rates
ranging from 0.7% to 47% (mean 15%).19 Another cross-sectionalFigure 1. Comparison of the human schistosomiasis prevalence rates in highly endemic zo
and of various other authors for the period 2002–2014 (right panel).survey of schistosomiasis was conducted in 2012 on 18 221 indi-
viduals residing in 22 schistosomiasis endemic villages in the
province of Northern Samar.20 Despite an active schistosomiasis
control programme in Northern Samar for over 30 years, which
included an MDA campaign in the last 5 years, the mean
prevalence of schistosomiasis among 10 435 subjects evaluated
was 27.1% (95% conﬁdence interval 26.3–28.0%).20 Moreover, a
cross-sectional ultrasound study in the same study location
showed high levels of schistosomiasis-induced morbidity in the
schistosomiasis endemic communities. Left lobe liver enlargement
(70 mm) was evident in 89.3% of subjects. Twenty-ﬁve percent
of the study population had grade II/III liver parenchyma ﬁbrosis
and 13.3% had splenomegaly (100 mm).20,21 In 2012, two
communities in the province of Cagayan (Magraﬁl and Santa
Maria) were screened for the prevalence of schistosome infection
and this was found to be 10% and 31%, respectively (personal
correspondence).22
5. Discussion
The recently reported national human prevalence (and GIS risk
maps) of schistosomiasis in the Philippines has been estimated
to be less than 3% in the endemic regions of the country.8,16 As
a result, the disease is no longer considered to be a major public
health problem by the government. Moreover, it is now
recommended that the limited national control funds be spent
on more targeted MDA, leading to disease elimination.16 However,
when one examines more closely how the national surveys were
conducted and how the current national programme is being
deployed, it is difﬁcult to ascertain by what means that national
prevalence could have dropped to such a low rate over the past
decade. Moreover, other studies over the past decade (2002–2014)
have shown evidence that the disease remains highly endemic
throughout the country in both human and bovine populations,
with reported human prevalence rates as high as 50% in somenes of the Philippines: Leonardo et al.8 (left panel), Magalha˜es et al.16 (centre panel),
Table 2
Key infection outcomes of studies investigating Schistosoma japonicum infection in humans in the Philippines
Year Study description Key outcomes Reference
2000 Immune correlate study on human S. japonicum in a well-deﬁned population in
Leyte, Philippines; 1262 out of 1699 individuals aged 15–30 years from three
study villages were examined for S. japonicum infection.
Prevalence of infection among 15–30-
year-olds was 60%
Acosta et al.17
2005 A cross-sectional survey of S. japonicum infection was carried out in 50 irrigated
and rain-fed villages in Western Samar Province, Philippines, as part of the
Schistosomiasis Transmission Ecology Project (STEP). The survey was
performed using a household cluster sampling technique.
Prevalence ranged from 0.7% to 47%
(mean 15%)
Tarafder et al.19
2008 Between 2008 and 2012 in Leyte, pregnant women were examined for S.
japonicum infection as part of the screening process for enrolment in the study
entitled, ‘‘The impact of praziquantel given at 12–16 weeks of gestation on
pregnancy outcomes: a double blind placebo controlled trial’’.
373 out of 1468 (25.4%) pregnant
women were positive for
schistosomiasis
Olveda et al.18
2012 In Northern Samar Province, cross-sectional surveys were performed to
determine the prevalence of S. japonicum infection in 22 endemic villages in the
municipalities of Palapag and Laoang, as part of the baseline study for the
project entitled, ‘‘Towards sustainable control and elimination of
schistosomiasis in the Philippines’’.
Prevalence of S. japonicum infection
ranged from 5% to 46% (mean 27%)
Ross et al.20
2013 A cross-sectional ultrasound survey in schistosomiasis endemic villages in the
municipality of Palapag, Northern Samar Province, was performed to determine
the prevalence of the different degrees of hepatic ﬁbrosis in the residents under
study.
Severe hepato-splenic morbidities
including grades II and III
schistosomiasis hepatic ﬁbrosis was
seen in 18% of the population
Olveda et al.21
2013 In Cagayan valley, in the northern part of the Philippines, a cross-sectional
survey of S. japonicum was conducted in two villages (Magraﬁl and Santa Maria)
as part of a baseline study for the project called, ‘‘Echohealth approach towards
the control of schistosomiasis in the Philippines’’.
The prevalence of infection in these two
villages was 10% and 31%, respectively
Olveda et al.22
2014 A diagnostic study of S. japonicum endemic villages in Northern Samar Province
was conducted in 2012. Faecal samples were collected from 560 humans and
examined by KK method and real-time PCR (qPCR) assay.
A high human prevalence rate (90.2%)
was recorded by qPCR, while the KK
method indicated a prevalence of 22.9%
Gordon et al.15
KK, Kato–Katz thick smear.
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zoonotic nature of the disease, it is difﬁcult to ignore such
evidence. Clearly, this discrepancy in reported ﬁndings warrants
closer scrutiny given the implications for national control and
future policy.
It is noteworthy that the recent national surveys were based on
only one or two KK thick smear stool slides for those who provided
stool, thus this will lead to a gross underestimation of the true
prevalence. It has been estimated that a single KK misses
approximately 55% of light infections and that ﬁve KK smears
would be needed to detect 95% of such infections.23 ‘Intra-
individual’ variation has been observed in repeated egg counts.23
Additionally, it has been shown that a small number of individuals
in endemic communities excrete a large proportion of eggs. This
‘inter-individual’ variation in egg counts is thought to reﬂect the
variation in worm loads.23 Quality control in reading such slides
is paramount if one wants to truly determine the underlying
prevalence in an endemic population. In the Philippines, based on
the personal research experience of the present investigators, the
ability of microscopists to correctly identify schistosomiasis eggs
varies considerably (0–60%) among trained personnel; thus, if
quality measures are not in place, this again will lead to a gross
underestimation of the human prevalence.
The national schistosomiasis control programme, using MDA of
humans as the sole strategy, has stated that the human prevalence
has dropped dramatically over the past decade. However, the
evidence for such a claim is weak given that less than a third of the
human population residing within endemic zones are currently
being treated annually and only a third of those treated actually
take the drug. For those who take the drug at the single oral dose
of 40 mg/kg, the estimated cure rate is 52% based on a recent
meta-analysis.4 In sum, approximately 5% of the endemic human
population is in reality receiving the appropriate treatment.
Moreover, in these same endemic communities, most of the
bovines are currently infected (>75%) but are not being treated
under the current control programme. Given this evidence, it is
believed that the prevalence of schistosomiasis has been grosslyunderestimated within endemic areas. Through the present
authors’ own research, it has been found that the disease is
moderately endemic (5–25%) in most endemic regions.14,15,17–20
6. Conclusions
Schistosomiasis remains a major public health problem in the
Philippines despite recent published reports. Given the zoonotic
nature of the disease, mass drug administration in humans as a
sole national control strategy will not lead to disease elimination.
An integrated national control programme that carefully considers
the role of bovines in human transmission, along with irrigation,
focal mollusciciding, annual mass drug administration of both
humans (60 mg/kg) and bovines (25 mg/kg), and health education
is advocated. Although this intersectoral approach will require a
substantial effort, it is the only strategy that will lead to
sustainability.
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